Literature DB >> 21229362

Increased peripheral Th17 in patients with pustulosis palmaris et plantaris.

Kan Torii1, Takuya Furuhashi, Chiyo Saito, Hiroshi Kato, Akiko Nishioka, Emi Nishida, Yoichi Shintani, Akimichi Morita.   

Abstract

Pustulosis palmaris et plantaris (PPP) is a chronic recurrent dermatitis characterized by intraepidermal pustules with erythematous scaling on the palms and soles. PPP shares many characteristics with psoriasis, but has a different genetic background. T helper 17 cells (Th17) have an important role in the pathogenesis of psoriasis. In psoriasis, regulatory T cells (Treg) are dysfunctional and circulating Th17 are increased. Whether Th17 are involved in PPP, however, is unclear. Therefore, we examined the Th17 population in peripheral blood mononuclear cells (PBMC) of patients with PPP. Foxp3(+) Treg was also analyzed. We examined circulating Th17 and Treg in the peripheral blood of PPP patients. PBMC were obtained from healthy volunteer controls (n = 26, mean ± SD age 33.11 ± 9.80 years) and PPP patients (n = 24, age 55.00 ± 12.26 years). The proportion of Th17 among the PBMC was 2.52 ± 0.811% (mean ± SD) in healthy controls and 3.23 ± 1.45% in PPP patients. The proportion of Th17 in the PPP patients was significantly higher than that in the healthy controls (p < 0.05, Student's t test). PPP patients had significantly fewer Treg (5.69 ± 1.86%) than healthy controls (7.10 ± 1.78%). Th17 was inversely correlated with Treg.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21229362     DOI: 10.1007/s00403-010-1112-x

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  5 in total

1.  Nummular dermatitis on guselkumab for palmoplantar psoriasis.

Authors:  Allison Truong; Stephanie Le; Maija Kiuru; Emanual Maverakis
Journal:  Dermatol Ther       Date:  2019-05-20       Impact factor: 2.851

2.  Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.

Authors:  Tadashi Terui; Satomi Kobayashi; Yukari Okubo; Masamoto Murakami; Keiichiro Hirose; Hiroshi Kubo
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

3.  Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.

Authors:  Yukari Okubo; Hitomi Morishima; Richuan Zheng; Tadashi Terui
Journal:  J Dermatol       Date:  2021-08-28       Impact factor: 3.468

4.  Relapse of Palmoplantar Pustulosis Following COVID-19 Vaccination.

Authors:  Shiho Katsuie; Kenta Nakamura; Eisaku Ogawa; Fuyuko Arakura; Ryuhei Okuyama
Journal:  Cureus       Date:  2022-08-30

5.  Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.

Authors:  T Yamamoto; K Fukuda; A Morita; T Kimura; H Morishima; R Goto; R Zheng; T Terui
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-15       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.